EP4472982A1 — Processes for the preparation of selective estrogen receptor degraders
Assigned to Eli Lilly and Co · Expires 2024-12-11 · 1y expired
What this patent protects
Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula (A), as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R 1 or R 2 is independently Cl, F,…
USPTO Abstract
Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula (A), as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R 1 or R 2 is independently Cl, F, -CF 3 , or -CH 3 , and the other is H; and R 7 is H or PG.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.